Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 411: What is the latest oral direct thrombin inhibitor?

A. Ximelagatran
B. Indraparinux
C. Dabigatran (Correct Answer)
D. Fondaparinux

Explanation: ### Explanation **Correct Answer: C. Dabigatran** **Mechanism and Rationale:** Dabigatran etexilate is a potent, competitive, and reversible **Direct Thrombin Inhibitor (DTI)**. Unlike heparin, which acts indirectly via antithrombin III, DTIs bind directly to the active site of both free and clot-bound thrombin (Factor IIa). It is administered as a prodrug and is currently the only orally available DTI approved for clinical use (e.g., for stroke prevention in atrial fibrillation and DVT prophylaxis). **Analysis of Incorrect Options:** * **A. Ximelagatran:** This was the first oral DTI developed. However, it was withdrawn from the market worldwide due to significant **hepatotoxicity** (elevation of liver enzymes). Dabigatran is the "latest" successful successor in this class. * **B. Idraparinux:** This is a long-acting synthetic polysaccharide that acts as an indirect **Factor Xa inhibitor**. It is administered subcutaneously, not orally. * **D. Fondaparinux:** This is a synthetic pentasaccharide that selectively inhibits **Factor Xa** by binding to antithrombin III. It is administered via subcutaneous injection and is not a thrombin inhibitor. **High-Yield Clinical Pearls for NEET-PG:** * **Reversal Agent:** The specific monoclonal antibody fragment used to reverse Dabigatran is **Idarucizumab** (Praxbind). * **Monitoring:** Unlike Warfarin, Dabigatran does not require routine INR monitoring. However, in emergencies, the **Diluted Thrombin Time (dTT)** or Ecarin Clotting Time (ECT) are the most sensitive tests. * **Excretion:** It is primarily eliminated by the **kidneys** (80%), so it must be used with caution or avoided in severe renal impairment. * **Comparison:** Remember the "Gatrans" (Dabigatran) are Thrombin (IIa) inhibitors, while the "Xabans" (Rivaroxaban, Apixaban) are Factor Xa inhibitors.

Question 412: Which of the following is most useful for reversing ergot-induced vasospasm?

A. Ergotamine
B. Methysergide
C. Nitroprusside (Correct Answer)
D. Phenoxybenzamine

Explanation: **Explanation:** **1. Why Nitroprusside is the Correct Answer:** Ergot alkaloids (like ergotamine) cause intense, prolonged peripheral vasoconstriction primarily by acting as partial agonists at **$\alpha$-adrenergic receptors** and **5-HT receptors** in vascular smooth muscle. This can lead to "ergotism," characterized by limb ischemia and gangrene. **Sodium Nitroprusside** is a potent, direct-acting mixed vasodilator (venous and arterial). It acts as a **nitric oxide (NO) donor**, which increases intracellular cGMP, leading to smooth muscle relaxation. It is considered the drug of choice for ergot-induced vasospasm because it acts directly on the vascular wall, bypassing the receptors occupied by ergot alkaloids, and provides rapid, titratable relief of the spasm. **2. Why the Other Options are Incorrect:** * **A. Ergotamine:** This is the causative agent. Administering more would worsen the vasospasm and ischemia. * **B. Methysergide:** This is an ergot derivative used for migraine prophylaxis. It has similar vasoconstrictive properties and is associated with retroperitoneal fibrosis; it would exacerbate the condition. * **C. Phenoxybenzamine:** While it is an irreversible $\alpha$-blocker, it is less effective than nitroprusside in this scenario because ergot-induced spasm involves multiple receptor types (serotonergic and adrenergic). Nitroprusside’s direct action is more reliable. **3. NEET-PG High-Yield Pearls:** * **St. Anthony’s Fire:** The historical term for ergot poisoning, referring to the burning sensation in ischemic limbs. * **Drug of Choice for Hypertensive Emergency:** Sodium Nitroprusside (though being replaced by Fenoldopam/Labetalol in some settings due to cyanide toxicity). * **Nitroprusside Toxicity:** Prolonged infusion can lead to **Cyanide and Thiocyanate toxicity**. The antidote is Sodium Thiosulfate or Hydroxocobalamin. * **Other treatments for Ergotism:** IV Heparin (to prevent secondary thrombosis) and Calcium Channel Blockers.

Question 413: What is the mechanism of action of digitalis in atrial fibrillation?

A. Causing bradycardia
B. Na+ K+ ATPase inhibition
C. Increase in refractoriness of the AV nodal tissue (Correct Answer)
D. Causing bradycardia

Explanation: **Mechanism of Action of Digitalis in Atrial Fibrillation** **Explanation of the Correct Answer:** In Atrial Fibrillation (AF), the atria generate rapid, disorganized electrical impulses (350–600 bpm). The primary goal of therapy is **rate control**, not rhythm conversion. Digitalis (Digoxin) achieves this through its **vagomimetic (parasympathomimetic) action**. It increases vagal tone, which slows conduction velocity and **increases the effective refractory period (ERP) of the AV node**. By making the AV node "busy" or unresponsive for longer periods, fewer atrial impulses reach the ventricles, thereby slowing the ventricular rate. **Analysis of Incorrect Options:** * **Option B (Na+ K+ ATPase inhibition):** While this is the primary molecular mechanism of Digoxin, it explains the **positive inotropic effect** (used in heart failure). In the context of AF, the therapeutic benefit is derived from its indirect electrophysiological effects on the AV node, not directly from enzyme inhibition in the myocytes. * **Options A & D (Causing bradycardia):** While Digoxin does cause a decrease in heart rate, "bradycardia" is a clinical sign/result rather than the *mechanism*. In NEET-PG, always prioritize the specific electrophysiological change (refractoriness) over the clinical outcome. **High-Yield Clinical Pearls for NEET-PG:** * **Vagal Dependence:** Digoxin is less effective for rate control during exercise or sympathetic stress because its action is dependent on resting vagal tone. * **Atrial Effects:** Paradoxically, Digoxin *shortens* the refractory period in atrial and ventricular muscle, which can occasionally worsen atrial arrhythmias or cause Ectopics/Bigeminy. * **Toxicity:** The earliest sign of Digoxin toxicity is usually gastrointestinal (anorexia, nausea), while the most characteristic visual side effect is **Xanthopsia** (yellowish vision). * **ECG Changes:** Look for the "reverse tick" or "Sagging ST segment" (Salvador Dali mustache sign).

Question 414: When nitrates are combined with calcium channel blockers, what is the expected effect on hemodynamics?

A. Systemic blood pressure will decrease (Correct Answer)
B. Heart rate will increase
C. Ejection time will decrease
D. End-diastolic volume will increase

Explanation: ### Explanation The combination of **Nitrates** and **Calcium Channel Blockers (CCBs)** is a common pharmacological strategy in managing angina pectoris. Both drug classes act as potent vasodilators, leading to a synergistic reduction in systemic vascular resistance. **1. Why Option A is Correct:** Nitrates primarily cause venodilation (reducing preload), while CCBs (especially dihydropyridines like Amlodipine) primarily cause arterial dilation (reducing afterload). When used together, their combined effect on the vascular smooth muscle leads to a significant reduction in total peripheral resistance and venous return, resulting in a **decrease in systemic blood pressure**. **2. Why the Other Options are Incorrect:** * **B. Heart Rate:** While Nitrates can cause reflex tachycardia, combining them with **non-dihydropyridine CCBs** (like Verapamil or Diltiazem) actually helps **decrease or neutralize** the heart rate. Therefore, an increase is not the expected combined hemodynamic goal. * **C. Ejection Time:** Nitrates tend to decrease ejection time, but CCBs (especially those with negative inotropic effects) can increase it. The net effect is usually neutral or balanced, making this an unreliable expected outcome. * **D. End-Diastolic Volume (EDV):** Nitrates significantly **decrease EDV** by increasing venous capacitance (pooling blood in the veins). This is a beneficial effect as it reduces myocardial oxygen demand. **Clinical Pearls for NEET-PG:** * **The "Perfect Match":** Nitrates cause reflex tachycardia and increased contractility; Beta-blockers or non-DHP CCBs are added to block these compensatory mechanisms. * **Contraindication:** Never combine Nitrates with **Sildenafil** (PDE-5 inhibitors) as it can lead to life-threatening hypotension. * **Nitrate Tolerance:** Prevented by providing a "nitrate-free interval" (usually 8–12 hours at night).

Question 415: Which of the following antiplatelet drugs is a P2Y12 receptor blocker not affected by CYP2C19 polymorphism?

A. Clopidogrel
B. Prasugrel (Correct Answer)
C. Eptifibatide
D. Dipyridamole

Explanation: **Explanation:** The correct answer is **Prasugrel**. **1. Why Prasugrel is correct:** Prasugrel is a third-generation thienopyridine P2Y12 receptor antagonist. Like clopidogrel, it is a prodrug; however, its metabolic activation is more efficient. It is rapidly hydrolyzed by esterases and then converted to its active metabolite by various CYP enzymes (primarily **CYP3A4 and CYP2B6**). Crucially, its activation is **not significantly dependent on CYP2C19**. Therefore, its antiplatelet efficacy is not affected by the genetic polymorphisms of CYP2C19 (poor metabolizers), leading to a more predictable and potent antiplatelet response compared to clopidogrel. **2. Why the other options are incorrect:** * **Clopidogrel:** This is a second-generation thienopyridine that relies heavily on a two-step hepatic activation process where **CYP2C19** plays a major role. Patients with a loss-of-function CYP2C19 allele are "poor metabolizers" and face a higher risk of cardiovascular events due to reduced active drug levels. * **Eptifibatide:** This is a **GP IIb/IIIa inhibitor**, not a P2Y12 blocker. It is administered intravenously and acts by preventing fibrinogen binding to platelets. * **Dipyridamole:** This drug acts primarily as a **phosphodiesterase (PDE) inhibitor**, increasing cAMP levels in platelets. It does not act on the P2Y12 receptor. **High-Yield Clinical Pearls for NEET-PG:** * **Ticagrelor** is another P2Y12 blocker not affected by CYP2C19 because it is **direct-acting** (not a prodrug) and binds reversibly. * **Prasugrel Contraindication:** It is strictly contraindicated in patients with a **prior history of stroke or TIA** due to a significantly increased risk of intracranial hemorrhage. * **Drug Interaction:** Avoid using **Omeprazole** (a CYP2C19 inhibitor) with Clopidogrel, as it reduces the antiplatelet effect. Pantoprazole is a safer alternative.

Question 416: Which drug is most likely to cause maximum tachycardia?

A. Nifedipine (Correct Answer)
B. Verapamil
C. Propranolol
D. Amlodipine

Explanation: The correct answer is **Nifedipine**. This question tests your understanding of the compensatory physiological responses to different classes of Calcium Channel Blockers (CCBs). **1. Why Nifedipine is correct:** Nifedipine is a **short-acting Dihydropyridine (DHP)**. It is a potent peripheral vasodilator. When administered, it causes rapid and significant peripheral vasodilation, leading to a sharp fall in blood pressure [1]. This triggers a robust **reflex sympathetic discharge**, resulting in marked **reflex tachycardia** [1]. Nifedipine also relaxes vascular smooth muscle at significantly lower concentrations than those required for prominent direct effects on the heart [1]. Because Nifedipine has negligible effects on the SA and AV nodes, there is no "braking" effect to counteract this sympathetic surge [2]. **2. Why the other options are incorrect:** * **Verapamil:** This is a Phenylalkylamine (Non-DHP) with significant **negative chronotropic and dromotropic** effects [3]. It acts directly on the SA node to slow the heart rate; therefore, it causes bradycardia rather than tachycardia [2, 3]. Verapamil and diltiazem interact kinetically with the calcium channel receptor in a different manner than the dihydropyridines; they block tachycardias in calcium-dependent cells, eg, the atrioventricular node, more selectively than do the dihydropyridines [2]. * **Propranolol:** A non-selective Beta-blocker. It decreases heart rate by blocking $\beta_1$ receptors in the heart, making it a cause of bradycardia. * **Amlodipine:** While also a DHP, Amlodipine is **long-acting** with a slow onset of action. Because the decline in blood pressure is gradual, the reflex sympathetic activation is much weaker compared to the rapid-acting Nifedipine. **High-Yield Clinical Pearls for NEET-PG:** * **Reflex Tachycardia Hierarchy:** Nifedipine (Short-acting) > Amlodipine (Long-acting). * **Clinical Caution:** Rapid-acting Nifedipine capsules are avoided in hypertensive emergencies/urgencies because the sudden reflex tachycardia and sympathetic surge can precipitate myocardial ischemia or MI. * **Drug of Choice:** Verapamil is a drug of choice for Supraventricular Tachycardia (PSVT) due to its potent action on the AV node. * **Combination Therapy:** Beta-blockers are often combined with DHPs to counteract reflex tachycardia.

Question 417: Which of the following is a selective myosin activator?

A. Istaroxime
B. Omecamtiv Mecarbil (Correct Answer)
C. Tolvaptan
D. Levosimendan

Explanation: **Explanation:** **Omecamtiv Mecarbil** is a novel **selective cardiac myosin activator** (cardiac inotrope) [1]. Unlike traditional inotropes, it does not increase intracellular calcium or cAMP. Instead, it binds directly to the catalytic domain of cardiac myosin, accelerating the rate-limiting step of the cross-bridge cycle (transition from the weak-binding to the strong-binding state). This increases the number of myosin heads bound to actin during systole, thereby increasing the **force of contraction** and **systolic ejection period** without increasing myocardial oxygen consumption or heart rate. **Analysis of Incorrect Options:** * **A. Istaroxime:** This is a dual-action investigational drug that inhibits Na+/K+ ATPase (like Digoxin) and activates the SERCA2a pump. It increases calcium sequestration but is not a direct myosin activator. * **C. Tolvaptan:** This is a selective **Vasopressin V2 receptor antagonist** (Aquaretic) used in the management of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD) [1]. * **D. Levosimendan:** This is a **Calcium Sensitizer** [1]. It binds to Troponin C, increasing the sensitivity of the contractile apparatus to existing calcium. It also acts as a K+ channel opener, causing vasodilation (Inodilator). **High-Yield Clinical Pearls for NEET-PG:** * **Omecamtiv Mecarbil** is specifically used in Heart Failure with Reduced Ejection Fraction (HFrEF) [1]. * **Key Advantage:** It improves cardiac function without the pro-arrhythmic risks associated with drugs that increase intracellular calcium (like Dobutamine or Milrinone). * **Mechanism Mnemonic:** "Omecamtiv **M**ecarbil **M**oves **M**yosin."

Question 418: Nicotinic acid acts by which of the following mechanisms?

A. Inhibiting the release of free fatty acids from adipose tissue (Correct Answer)
B. Inhibiting HMG-CoA synthatase
C. Inhibiting HMG CoA reductase
D. Decreasing absorption of cholesterol

Explanation: ### Explanation **Mechanism of Action (Correct Answer: A)** Nicotinic acid (Niacin) is a potent hypolipidemic agent that acts primarily on adipose tissue. It binds to a specific G-protein coupled receptor (**GPR109A/HM74A**), which inhibits adenylyl cyclase. This leads to a decrease in intracellular cAMP, thereby inhibiting **hormone-sensitive lipase**. The inhibition of this enzyme prevents the breakdown of triglycerides into free fatty acids (FFAs). Since fewer FFAs are released into the circulation, the liver has less substrate to synthesize VLDL, which subsequently leads to a reduction in LDL levels. **Analysis of Incorrect Options:** * **B & C (HMG-CoA Synthetase/Reductase):** These enzymes are involved in the rate-limiting steps of endogenous cholesterol synthesis in the liver. **Statins** (e.g., Atorvastatin) are the prototype drugs that inhibit HMG-CoA reductase. * **D (Decreasing absorption):** This is the mechanism of **Ezetimibe** (which inhibits the NPC1L1 transporter in the intestine) or **Bile acid sequestrants** like Cholestyramine (which prevent reabsorption of bile acids). **High-Yield Clinical Pearls for NEET-PG:** * **Lipid Profile:** Niacin is the most effective drug for **increasing HDL levels**. It also significantly reduces Triglycerides and Lipoprotein (a). * **Side Effects:** The most common side effect is **cutaneous flushing** and pruritus (mediated by Prostaglandin $D_2$ and $E_2$). This can be mitigated by pre-treating with **Aspirin**. * **Metabolic Concerns:** It can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (impaired glucose tolerance), so it should be used cautiously in diabetic patients. * **Acanthosis Nigricans:** Niacin is a known pharmacological cause of this skin condition.

Question 419: A patient presents to the medicine emergency with severe CHF. A drug is chosen which is a short-term ionotropic agent with selective adrenergic agonistic activity but lacking dopaminergic agonistic activity. What can this drug be?

A. Dopamine
B. Dobutamine (Correct Answer)
C. Amrinone
D. Salmeterol

Explanation: **Explanation:** The patient is presenting with severe Congestive Heart Failure (CHF), requiring an inotropic agent to improve cardiac output. **Why Dobutamine is correct:** Dobutamine is a synthetic catecholamine that acts as a **selective $\beta_1$-adrenergic agonist**. It increases myocardial contractility (positive inotropy) with a relatively lesser effect on heart rate (chronotropy). Crucially, unlike dopamine, it has **no action on dopaminergic ($D_1, D_2$) receptors**. It is the drug of choice for short-term management of cardiac decompensation post-surgery or in CHF/cardiogenic shock. **Why other options are incorrect:** * **Dopamine:** While it is an inotrope, it acts on **dopaminergic receptors** (causing renal vasodilation at low doses) as well as $\beta_1$ and $\alpha_1$ receptors. The question specifically excludes dopaminergic activity. * **Amrinone (Inamrinone):** This is a **Phosphodiesterase-3 (PDE3) inhibitor**, not an adrenergic agonist. It increases cAMP levels to exert inotropic effects but works via a different mechanism than the one described. * **Salmeterol:** This is a long-acting **$\beta_2$-selective agonist** used primarily as a bronchodilator in asthma/COPD; it is not used as an inotropic agent in acute CHF. **High-Yield Clinical Pearls for NEET-PG:** * **Dobutamine** is often preferred over Dopamine in cardiogenic shock because it reduces afterload (slight $\beta_2$ effect) and has a lower tendency to cause tachycardia. * **Isoprenaline** is a non-selective $\beta$-agonist ($\beta_1 = \beta_2$), whereas Dobutamine is $\beta_1$ selective. * **Tolerance:** Tachyphylaxis (decreased response) can occur with Dobutamine if used continuously for more than 72 hours due to receptor down-regulation.

Question 420: A 70-year-old female presents to the emergency department with chest pain. Her ECG shows ventricular tachycardia with ST-segment elevation, and troponin levels are elevated, leading to a diagnosis of STEMI. What is the initial treatment for the arrhythmia?

A. Lidocaine (Correct Answer)
B. Adenosine
C. Quinidine
D. Verapamil

Explanation: ### Explanation **Correct Option: A. Lidocaine** In the setting of an acute myocardial infarction (STEMI), the myocardium becomes ischemic and acidic. **Lidocaine**, a Class IB antiarrhythmic, is the drug of choice for ventricular arrhythmias associated with acute MI. * **Mechanism:** It selectively binds to sodium channels in the **inactivated state**. Ischemic tissue stays depolarized longer, keeping channels in the inactivated state, which allows Lidocaine to preferentially block sodium entry in damaged cells while sparing healthy tissue. * **Key Concept:** It has little effect on normal conduction but effectively suppresses automaticity in ischemic ventricular fibers. **Why other options are incorrect:** * **B. Adenosine:** This is the drug of choice for Paroxysmal Supraventricular Tachycardia (PSVT). It acts on the AV node and is ineffective for ventricular arrhythmias. * **C. Quinidine:** A Class IA antiarrhythmic. It is contraindicated in MI because it can prolong the QT interval, potentially leading to Torsades de Pointes, and has significant anticholinergic side effects. * **D. Verapamil:** A Calcium Channel Blocker (Class IV). It is used for rate control in atrial arrhythmias (like AFib) but is contraindicated in ventricular tachycardia as it can precipitate severe hypotension and cardiovascular collapse. **NEET-PG High-Yield Pearls:** * **Class IB (Lidocaine, Mexiletine):** "IB is Best post-MI." They have the shortest recovery time from channel binding. * **Route:** Lidocaine must be given **IV** due to extensive first-pass metabolism. * **Toxicity:** Overdose primarily affects the CNS (seizures, tremors, slurred speech). * **Current ACLS Guidelines:** While Amiodarone is now often used first-line for stable VT, Lidocaine remains the classic pharmacological answer for **ischemia-induced** ventricular arrhythmias in exam scenarios.

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free